June 11, 2019
This summer, as part of our commitment to broad stakeholder education about the promise of biosimilars, the Biosimilars Council will launch the first in a series of “member spotlights” – in-depth content featuring experts from our member companies sharing their unique experience and perspective on timely issues impacting the emerging biosimilars marketplace.
AAM and the Biosimilars Council Statement on UnitedHealthcare Announcement to Reverse Course on Biosimilars
May 30, 2019
UnitedHealthcare’s (UHC) recent announcement that it will begin preferring brand name biologics over lower priced FDA-approved biosimilars is a step backwards in patient care.
May 17, 2019
We look forward to continuing to work with CMS to align coverage and payment policies to increase patient access to more affordable biosimilar and generic medicines.
May 16, 2019
This paper outlines those challenges and recommends actions for policymakers to foster the development of biosimilar insulins for America’s patients.
May 13, 2019
We encourage the FDA to to build on its significant experience with insulin and foster efficient development of biosimilar insulins to lower costs and increase access for America’s diabetes patients.
May 13, 2019
The current insulin market lacks significant competition to the detriment of patient access and health and has been characterized as a public health crisis.